Development of an in vivo antibody-mediated killing (IVAK) model, a flow cytometric method to rapidly evaluate therapeutic antibodies
CA Guyre, D Gomes, KA Smith, JM Kaplan… - Journal of …, 2008 - Elsevier
The efficacy and mechanism of action of therapeutic antibodies that target cancer cells have
typically been evaluated using in vitro assays and long-term in vivo tumor models. To allow
for a more efficient assessment of the function of candidate therapeutic antibodies, we have
developed a flow cytometric-based method that rapidly and directly quantifies antibody-
mediated killing in a short term in vivo assay. Target cells that express human CD52,
including huCD52+ splenocytes from huCD52 transgenic mice and Ramos cells, a CD52+ …
typically been evaluated using in vitro assays and long-term in vivo tumor models. To allow
for a more efficient assessment of the function of candidate therapeutic antibodies, we have
developed a flow cytometric-based method that rapidly and directly quantifies antibody-
mediated killing in a short term in vivo assay. Target cells that express human CD52,
including huCD52+ splenocytes from huCD52 transgenic mice and Ramos cells, a CD52+ …
